XOMA Corp
NASDAQ:XOMA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.79
32.46
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one XOMA stock under the Base Case scenario is 35.65 USD. Compared to the current market price of 31.26 USD, XOMA Corp is Undervalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
XOMA Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for XOMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
XOMA Corp
Balance Sheet Decomposition
XOMA Corp
Current Assets | 159m |
Cash & Short-Term Investments | 142.8m |
Receivables | 13.7m |
Other Current Assets | 2.5m |
Non-Current Assets | 64.3m |
PP&E | 369k |
Other Non-Current Assets | 64m |
Current Liabilities | 21.1m |
Accounts Payable | 1.1m |
Accrued Liabilities | 2.9m |
Other Current Liabilities | 17.1m |
Non-Current Liabilities | 117.4m |
Long-Term Debt | 108.1m |
Other Non-Current Liabilities | 9.3m |
Earnings Waterfall
XOMA Corp
Revenue
|
23.1m
USD
|
Operating Expenses
|
-41.9m
USD
|
Operating Income
|
-18.8m
USD
|
Other Expenses
|
-23.6m
USD
|
Net Income
|
-42.4m
USD
|
Free Cash Flow Analysis
XOMA Corp
USD | |
Free Cash Flow | USD |
XOMA Profitability Score
Profitability Due Diligence
XOMA Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
XOMA Corp's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
XOMA Solvency Score
Solvency Due Diligence
XOMA Corp's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
XOMA Corp's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XOMA Price Targets Summary
XOMA Corp
According to Wall Street analysts, the average 1-year price target for XOMA is 84.66 USD with a low forecast of 49.49 USD and a high forecast of 122.85 USD.
Dividends
Current shareholder yield for XOMA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
XOMA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.
Contact
IPO
Employees
Officers
The intrinsic value of one XOMA stock under the Base Case scenario is 35.65 USD.
Compared to the current market price of 31.26 USD, XOMA Corp is Undervalued by 12%.